Antidiabetic thiazolidinediones (TZDs) improve endothelial function in patients with or without type 2 diabetes. The present randomised, placebo-controlled, double-blind study examined the time course of a single dose of rosiglitazone on flow-mediated endothelium-dependent vasodilation (FMD), metabolic parameters, and its effect on inflammatory markers in non-diabetic men. Forty non-obese, healthy men with normal glucose tolerance were randomised to a single dose of rosiglitazone (8 mg) or placebo, and FMD was assessed at baseline as well as after 6 h and 24 h. Rosiglitazone did not significantly affect blood glucose and insulin levels or lipid parameters after 6 and 24 h compared with placebo. Treatment with rosiglitazone significantly increased FMD after 6 h from 4.3% (3.3; 4.9) to 7.6% (5.6; 9.2) (p<0.0001 vs. baseline) resulting in a highly significant effect compared with placebo (p<0.0001 for difference between groups). After 24 h FMD was still significantly higher in the rosiglitazone group compared with baseline (p=0.001), but the effect was no longer statistically significant versus placebo (p=0.171). Our study shows a very rapid effect of single dose rosiglitazone treatment on endothelial function in non-diabetic healthy men, underscoring the hypothesis that TZDs may exhibit direct effect in the vasculature independent of their metabolic action.
Introduction
Normal endothelial function is of critical importance for the maintenance of vascular homeostasis and the regulation of blood pressure and vascular tone. Regular endothelial function mainly depends on the capacity of endothelial cells to produce NO. Various mediators and, probably most important from a physiological point of view, an increase in shear stress induces the release of NO from endothelial cells, which leads to relaxation of neighbouring vascular smooth muscle cells with subsequent vasodilation. In addition to its vasodilatory function, NO exhibits vasoprotective effects in the vessel wall by limiting leukocyte adhesion, cytokine and chemokine expression, and smooth muscle cell migration as well as by reducing the expression of pro-thrombotic mediators on the endothelial surface. [1] [2] [3] [4] A loss of endothelium-derived NO release is accompanied by impaired endothelium-dependent vasodilation as well as by endothelial cell activation. This state, which is called endothelial dysfunction, is considered to be a critical step in early atherogenesis contributing to leukocyte recruitment with subsequent lesion formation. 5 Several pharmacological approaches such as statin or TZD treatment improve endothelial function, [6] [7] [8] thereby potentially influencing a critical step in early atherogenesis. Anti-diabetic TZDs such as rosiglitazone and pioglitazone influence endothelial function in patients with type 2 diabetes, as shown by an increase in FMD. [8] [9] [10] Interestingly, various studies have demonstrated that TZDs modulate endothelial function independently of their metabolic action on glucose and lipid metabolism. 11 Moreover, in a previous study, we have been able to show in 10 non-diabetic subjects that rosiglitazone treatment for 1 day already increased endothelium-dependent vasodilation, suggesting a direct effect of TZDs on the endothelium. 12 Indeed, in vitro studies have convincingly demonstrated that PPAR-γ activating TZDs enhance the release of NO from endothelial cells. 13 Still, the kinetics of an early effect of rosiglitazone on endothelial function in vivo is currently unexplored. Therefore the present study examined whether a single dose of rosiglitazone treatment may affect FMD in healthy non-diabetic subjects and whether this treatment may also influence serum levels of inflammatory biomarkers.
Research design and methods

Study population and study design
Forty healthy volunteers were recruited from the Department of Internal Medicine at the University of Ulm, Germany, and randomised to a single dose of rosiglitazone (8 mg) or placebo. Inclusion criteria were as follows: nondiabetic, non-obese, healthy men aged > 18 years without any other cardiovascular risk factor (hypertension, smoking, dyslipidemia). An oral glucose tolerance test was performed in all subjects to ensure a normal glucose tolerance. The study protocol was approved by the local ethics committee and all subjects gave written informed consent. The trial was registered: EudraCT number: 2006-005980-25.
Study participants were treated with rosiglitazone 8 mg or placebo as a single dose in the morning. Endothelial function was assessed at baseline, as well as after 6 h and 24 h of treatment. Inflammatory biomarkers were measured at baseline as well as after 1, 2, 4, 6, 8, 10 and 24 h. Participants were in a fasting state 12 h before baseline measurement and during the first 6 h of treatment. In addition, they were in a fasting state 12 h prior to the 24-h measurement of endothelial function.
Endothelial function testing
Standard FMD [14] [15] [16] was assessed as follows. All subjects were studied at rest in supine position. All measurements were performed in a quiet and temperature-controlled room (23°C) between 0600 and 0800 in the morning. We used a high-resolution ultrasound system (iU 22, Philips Medical Systems, Bothell, WA, USA) with an internal electrocardiography package. The diameter of the brachial artery was measured from two-dimensional ultrasound images using a 17 MHz linear array transducer (CL17-5, Phillips). Subjects had to rest for at least 15 min before the first scan was recorded. A pneumatic cuff was positioned just below the elbow. The brachial artery was scanned in longitudinal sections 2-4 cm above the elbow. Diameter measurements were done according to the guidelines for measuring FMD. 17 After measurement of baseline diameter and baseline flow, a pneumatic tourniquet was inflated on the forearm at least 50 mmHg above systolic pressure for exactly 5 min. Post-ischemic flow measurements were done immediately after cuff deflation; diameter measurements were done 45 to 60 s after cuff deflation. After an additional 10 min (to allow vessel recovery) the endothelium-independent dilatation was assessed 4 min after sublingual administration of 0.4 mg GTN.
ECG was monitored continuously. Vessel diameters were analysed with the use of electronic calipers on frozen images over a length of the artery of 1 cm. Three measurements were taken at each scan for four cardiac cycles at the end of the diastole (incident with the R wave on the ECG), and the mean was then calculated. The difference in lumen diameter between rest and reactive hyperaemia, expressed as percent change, was regarded as endothelium-dependent vasodilation, the difference at rest and after application of GTN in percent as endothelium-independent vasodilation.
Laboratory methods
Blood samples were taken after endothelial function testing. TNF-a, soluble-E-Selectin, adiponectin, and vWF (all R&D-Systems) were determined by ELISA according to the manufacturers' protocol. ADMA and L-arginine levels were measured by a fully validated, previously published method using liquid chromatography tandem mass spectrometry, which is commercially available (DLD Diag nostika, Hamburg, Germany). 18 SAA and CRP were measured as previously described. 19 Malonaldehyde was commercially measured (Immuno Diagnostics) and Carbonyl proteins were determined by ELISA according to the manufacturer's protocol (Immuno Diagnostics).
Statistical analysis
Samples' size was calculated based on the results of previous trials examining the effect of TZDs on endotheliumdependent vasodilation in diabetic subjects, 10, 20 as well as on data from our own previous study in 10 non-diabetic subjects. Based on these studies we assumed a FMD after arterial forearm compression of 5% at baseline with a 90% increase after treatment, resulting in 20 subjects to receive statistical significance with 80% power (a=0.05). Differences between treatment time-points were calculated using Friedman RM ANOVA or one-way repeated measurement ANOVA followed by the appropriate post-hoc test. Skewed data are reported as median (interquartile range); all other data as mean ±SD. A p value < 0.05 was regarded as significant.
Results
Single-dose rosiglitazone treatment rapidly increases FMD
Study participants did not differ with respect to baseline characteristics (table 1). After 6 h, fasting plasma glucose, fasting insulin, as well as HOMA-IR significantly decreased in both groups compared with baseline, but no significant difference was found between groups after 6 and 24 h. In addition, groups did not significantly differ with respect to total cholesterol, HDL cholesterol, LDL cholesterol or triglycerides at these time points (table 2) .
Before treatment, FMD was within the normal range and did not significantly differ between the two groups (placebo group: 4.7% (4.5; 6.2); rosiglitazone group: 4.3 (3.3; 4.9)%). Treatment with rosiglitazone significantly increased FMD after 6 h to 7.6% (5.6; 9.2) (p < 0.0001 vs. baseline). In contrast, in the placebo group FMD significantly decreased after 6 h to 4.1% (3.1; 5.1) (p < 0.0001). At this timepoint of 6 h after treatment, the difference between groups was highly significant (p < 0.0001) ( figure 1A ). After 24 h FMD was still significantly higher in the rosiglitazone group compared with baseline (p = 0.001), but the effect was no longer statistically significant versus placebo (p = 0.171). In addition, rosiglitazone significantly decreased post-ische mic systolic blood flow after 6 h compared with placebo (p = 0.01) ( figure 1B) . A similarly significant effect was observed for the diastolic blood flow (p < 0.05 for comparison between groups) ( figure 1C) . Given that various studies already showed that TZD treatment does not affect endotheliumindependent vasodilation, 10, 12 we did not treat our study participants with GTN during the 24-h study period to avoid potential confounding effects on endothelial function and the levels of biomarkers. After the last measurement, 24 h after treatment, we assessed endothelium-independent vasodilation by giving GTN and did not find a difference between groups (placebo group: 16.2% (11.7; 19.0); rosiglitazone group: 16.3% (13.0; 19.1); p = 0.394).
Next we examined whether rosiglitazone's rapid effect on endothelium-dependent vasodilation was accompanied by changes in the serum levels of ADMA and L-arginine. As shown in table 3, rosiglitazone did not significantly affect ADMA and L-arginine levels after 6 and 24 h. Moreover, rosiglitazone did not significantly change serum levels of the endothelium-related biomarkers sE-selectin and vWF compared with placebo, despite a significant effect of rosiglitazone on sE-selectin levels after 6 h compared with baseline. To investigate whether the effect of rosiglitazone on endothelial function may be mediated by changes in oxidative stress, we measured serum levels of malonaldehyde and carbonyl proteins, but could not detect significant changes by short-term treatment (table 3) . Next we measured serum levels of the pro-inflammatory cytokine TNF-a, as well as levels of the vasculoprotective adipokine adiponectin. Rosiglitazone did not significantly alter TNF-a and adiponectin levels, nor did it affect serum levels of hsCRP and SAA, two additional inflammatory biomarkers.
Discussion
This randomised, placebo-controlled, double-blind study demonstrates that single-dose rosiglitazone treatment of healthy subjects rapidly increases endothelium-dependent vasodilation. These effects were not accompanied by changes in metabolic parameters nor by changes in serum levels of inflammatory or endothelial-related biomarkers.
The effect on endothelium-dependent vasodilation in healthy, non-diabetic, non-obese subjects already occurred after 6 h of single-dose rosiglitazone treatment. Previous studies in diabetic subjects, as well in those with the metabolic syndrome, have shown that TZDs improve endothelium-dependent vasodilation after 8-16 weeks of treatment, with these effects being paralleled by an improvement in insulin sensitivity and a decrease in blood glucose levels. 8, 11 Moreover, recent data from Kanda et al. suggest that TZDs mediate metabolic and vascular responses directly. 21 A recent study from our group has demonstrated a significant effect of rosiglitazone after 1 day of treatment (4 mg rosiglitazone BID) in healthy, non-diabetic men without any changes on glucose metabolism or lipid profile, suggesting a direct effect on the endothelium, independent of any metabolic action. 12 The present study now extends our understanding on TZDs' effects on endothelial function by showing a rapid effect a few hours after a single dose of rosiglitazone. This effect is most likely not related to any glucose or lipid-lowering properties of the TZD employed: first, we excluded any glycaemia disorder in our study population by performing an oral glucose tolerance test before study entry; in addition, we did not find any changes in glucose and insulin levels after 6 and 24 h of treatment between groups. This is consistent with previous findings showing that short-term TZD treatment of healthy subjects does not have an effect on glucose metabolism. 22 In addition, rosiglitazone treatment did not significantly alter total cholesterol, LDL cholesterol, HDL cholesterol, or triglyceride levels. The metabolic effects of TZDs usually occur after several weeks of treatment, 23 while the improvement in vasodilatory function observed here is already present after 6 h. Finally, some of the metabolic effects of TZDs are considered to be mediated via an increase in adiponectin levels, 24, 25 but we did not find any significant changes between treatment groups at any time point, making such changes an unlikely explanation for our finding. Previous studies reported higher baseline values in FMD in healthy subjects than those measured in our population. 26 Still, our previous study in healthy subjects 12 as well as a recent study by Otto et al. also demonstrated low values (4.4 ± 0.7%) of FMD early in the morning. 27 Our data with a baseline value of 4.7% (4.5; 6.2) were assessed between 6 and 8 am, and are therefore in line with these latter results. In the placebo group, FMD decreased after 6 h, but this may be due to the circadian rhythm of endothelial function and the fact that all subjects were in a fasting state for these measurements. However, given a highly significant effect of rosiglitazone at this time point versus baseline, we can exclude that the difference between the two groups is only due to changes in the placebo group.
The rapid increase in endothelium-dependent vasodilation is not paralleled by significant changes in serum markers of endothelial function such as sE-selectin or vWF between groups. This is in contrast to our previous study in which we saw a decrease of sE-selectin levels after 1 day of rosiglitazone treatment. 12 Given the long half-life of sEselectin (12-24 h) 28 and the half-life of rosiglitazone in humans (3-4 h elimination half-life), a second dose of rosiglitazone in the evening (as used in our previous study, in which study subjects were treated with rosiglitazone 4 mg twice a day) might have reduced sE-selectin levels to a greater extent after 24 hours. In addition, the lack of an effect on serum levels of the proinflammatory cytokine TNF-a as well as on the biomarkers hsCRP and SAA make indirect anti-inflammatory effects of rosiglitazone also an unlikely explanation for the effects on endothelial function.
The rapid beneficial effect of rosiglitazone on endothelium-dependent vasodilation observed here suggests that TZDs may directly modulate endothelial activation. Since FMD is mediated by an increased availability of NO, 3 rosiglitazone treatment may directly enhance NO production in the endothelium. Indeed, in vitro data have shown that TZDs augment the release of NO from endothelial cells. 13 However, the significant effect on NO release in vitro was seen after 16 h, while we found an improvement of To further elucidate the underlying mechanisms for our observation, we measured ADMA, an endogenous inhibitor of NO, as a marker of endothelial activation and impaired NO bioavailability. 29 Previously, a small uncontrolled trial in seven patients with insulin resistance showed that 12 weeks of rosiglitazone treatment significantly decreased ADMA levels, 30 and more recently, Wang and his colleagues reported that treatment with rosiglitazone for 8 weeks (4 mg/day) significantly reduced ADMA levels in non-diabetic patients with the metabolic syndrome. 31 In the latter study, the reduction in ADMA levels correlated with the improvement in endothelium-dependent vasodilation, suggesting that rosiglitazone-mediated changes in ADMA levels might contribute to the effect on vascular function. In contrast to these findings, we did not find an effect on ADMA levels. This may be due to the fact that the healthy participants in our study exhibited normal ADMA levels and that the treatment period may have been too short to affect ADMA levels. Alternatively, the effects on FMD may be due to an anti-oxidative effect of rosiglitazone, as recently suggested for other TZDs 32 However, short-term treatment with rosiglitazone did not significantly change serum levels of the established oxidative stress parameters malonaldehyde and carbonyl proteins in our study. Thus, future studies are warranted to further elucidate the underlying mechanisms for our observation.
Overall, our data are in line with previous studies suggesting beneficial effect of TZDs on vascular surrogate markers in non-diabetic patients. As such, TZDs have been shown to reduce CRP, fibrinogen, [33] [34] [35] and vWF levels, 36 limit circulating platelet activity, 37 and reduce carotid intima media thickness progression and restenosis in nondiabetic patients with or without coronary artery disease. 36 Interestingly, recent meta-analyses on CV events in rosiglitazone-treated patients raised the hypothesis that this particular TZD might increase the risk for myocardial infarction and CV death. 38, 39 However, the subsequently published interim analysis of a randomised, prospective CV outcome trial with rosiglitazone (RECORD) could not confirm such results. 40 Therefore, the data on CV events in rosiglitazone-treated patients remain inconclusive, and upcoming studies with rosiglitazone will shed more light on this issue.
In summary, our placebo-controlled study in a population of non-diabetic, non-obese, healthy men suggests that rosiglitazone exhibits a rapid and direct effect on endothelial function. The ongoing cardiovascular outcome trials with rosiglitazone will reveal whether such potential protective effects may translate into clinical benefits and improve the prognosis of treated patients.
